keloid
Conditions
Interventions
KD itching group:none
KD non-itching group:none
Healthy control group:none
Sponsors
Dematology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Meeting the criteria for keloids as specified in the Clinical Practice Guidelines for the Management of Keloids in China: pathological scar tissue that is secondary to skin trauma, arises from spontaneous formation, and exhibits excessive growth. The lesion extends beyond the boundaries of the original skin injury and shows continuous growth. Clinically, it presents as a nodular, cord-like, or plaque-like mass-like tissue that is elevated above the skin surface, firm and tough in texture, and hyperemic. 2. Gender: No restriction; Age: 16-65 years of age; 3. No restrictions on the location of growth or size of keloids; without infection or ulceration.(Itch group: NRS >= 4, with a duration of >= 1 month; Non-itch group: NRS = 0, no keloid-specific treatment in the past 6 months, and no administration of antihistamines or other antipruritic drugs.); 4. The patient agrees to complete professional medical records and questionnaires, and to allow the postoperatively excised medical waste materials (keloids and surrounding tissues) to be used in this study. 5. Patients sign the informed consent forms (for those under 18 years of age, both their guardians and the minors themselves are required to sign); Control group: 1. Patients with pigmented nevi without any other underlying diseases. 2. No gender limitation; aged 16-65; without itching symptoms. 3. Patients agree to allow the postoperative excised medical waste (pigmented nevi and surrounding tissue) to be used for this study and sign the informed consent form (for those under 18, both the guardian and the minor must sign).
Exclusion criteria
Exclusion criteria: 1.Individuals who suffer from severe mental illnesses (such as schizophrenia, major depressive disorder, etc.) and are unable to accurately express their own pruritus sensations. 2.Individuals with comorbid eczema, urticaria, psoriasis, and other skin diseases that may cause pruritus. 3.Female patients who are in pregnancy or lactation. 4.Individuals with comorbid severe dysfunction of vital organs such as the heart, liver, and kidneys. Control group: Severe liver and kidney dysfunction, post-transplant; history of tumors, such as lymphoma, hematological diseases, etc.; patients with infectious diseases; severe infections like HIV, tuberculosis; other autoimmune diseases, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunology phenotype;peak pruritus numeric rating scale;Vancouver Scar Scale; | — |
Countries
China
Contacts
Public ContactFang Wang
Dematology Hospital of Southern Medical University
Outcome results
None listed